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To identify CNVs of potential etiologic relevance that include glutamatergic genes, we crossed the information available in public databases on synaptic 
pathways (Kyoto Encyclopaedia of Gene and Genomes database) and the results of a large genomic screening for CNVs, carried out by the Autism 
Genome Project (AGP) in 2184 ASD patients and 8000 healthy controls. In a subset of 342 Portuguese ASD probands, the most interesting CNVs were 
validated by quantitative or Long Range PCR and clinical correlations further explored.  
Generally, deletions have an higher impact in gene function than duplications. 
Here we show that genes shared between pathways are more prone to deletions 
which may suggest that one single CNV may, in fact, interfere with more than one 
synaptic pathway and have more serious functional consequences.   
The present results show more structural alterations encompassing glutamatergic 
genes relatively to other synaptic pathways , specially those encoding proteins 
present at the postsynaptic level, reinforcing the putative role of the glutamate 
pathway in ASD.   
Copy Number Variants (CNVs) play an important role in susceptibility to Autism Spectrum Disorders (ASD), in particular when deleting or duplicating 
genes involved in synaptic structure and function such as glutamatergic synapse genes. Identifying CNVs of etiologic relevance for ASD that include 
glutamatergic genes may contribute to the understanding of glutamate-related pathogenic mechanisms in this disorder.  
We identified a total of 294 CNVs, absent or overlapping 
less than 20%  with CNVs in 8000 control subjects from 
available databases, that duplicate or delete genes involved 
in the glutamatergic, dopaminergic, serotonergic, 
cholinergic or gabaergic synaptic pathways (Figure 1). These 
CNVs included 181 deletions and 113 duplications. Some 
genes are shared by several synaptic pathways, while others 
are specifically involved in the function or structure of a 
type of  synapse.  Our  results show that genes shared 
between pathways are more prone to suffer deletions 
(Figure 2A).  This is also true for glutamatergic, 
serotonergic and cholinergic pathway-specific genes, while 
gabaergic and dopaminergic pathway genes presented an 
higher percentage of duplicating events (Figure 2B).  
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Figure1.  CNVs deleting or duplicating genes in synaptic pathways identified in ASD probands. 
Glutamatergic pathway genes are the most frequently deleted, while duplications are more frequent in 
gabanergic genes. 
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Figure2.  CNV events involving shared (A) and pathway-specific (B) genes.  A single CNV encompassing a 
gene that is shared between several pathways is likely to be of etiological relevance.  
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Looking specifically at the glutamatergic synapse, we 
identified a total of 115 CNVs, including 86 deletions and 29 
duplications, encompassing coding genes for proteins 
involved in glutamatergic neuronal excitability and synaptic 
plasticity processes (Figure 3 and Table 1). Of these, 20 (14 
deletions and 6 duplications) were present in Portuguese 
probands.  
We validated two de novo microdeletions of GRIN3A and 
SHANK3 genes, and maternally or paternally inherited 
microdeletions of GRID2 and RGS7 genes; two duplications of 
the ACDY7 gene, one de novo and another present in both 
parents, and a duplication of the RGS4 gene with maternal 
inheritance. Validation of the remaining CNVs is ongoing. The 
probands with CNVs in ACDY7, SHANK3 and RGS4 genes had 
a positive family history of ASD and learning difficulties. Three 
patients presented intellectual disability, but none had 
epilepsy, although probands with the RGS4 and ACDY7 
duplications revealed an altered neurological exam and MRI, 
respectively. Overall, there was no distinct clinical phenotype 
associated with these alterations. 
GLUTAMATERGIC SYNAPSE 
Figure 3.  Glutamatergic synapse. The CNV identifyed involved genes encoding 
proteins engaged on synaptic comunication mediated by glutamate. 
(Adapted from: http://www.genome.jp/kegg/pathway.html) 
Table1.  CNVs affecting genes component of the glutamatergic synapse 
PROTEIN FAMILY DELETIONS (N) DUPLICATIONS (N) 
AC (Adenylyl cyclase class 4/guanylyl cyclase) ADCY2 (2) ADCY5 (1);  ADCY7 (2)  
GRK (Protein kinase – protein-coupled receptor kinase) ADRBK1(4);  ADRBK2 (2)   - 
GLS  (Glutaminase)   - GLS (1)  
Gq (G-protein – Guanine nucleotide-binding protein alpha)  - GNAQ (1)  
Gi/o (G-protein – Guanine nucleotide-binding protein gamma) GNG2 (5)  GNG2 (2)  
AMPA (Glutamate-gated ion chanel – ianotropic glutamate 
transmembrane receptor) 
GRIA2 (3); GRID2 (1)   GRID2 (1) 
KA (Glutamate-gated ion chanel – Ianotropic glutamate 
receptor) 
GRIK2 (3); GRIK3 (1); GRIK4 (2) GRIK2 (1) 
NMDAR (Glutamate-gated ion chanel – NMDA receptor 
subtype)  
GRIN3A (2); GRIN3B (5) GRIN3B (2) 
mGLUR (G-protein coupled receptor – Glutamate receptor) GMR5 (5); GMR7 (1)  GMR5 (2); GMR8 (1)  
IP3R  (InsP3 receptor) ITPR3 (1)   - 
PLA2 (Phospholipase – Phospholipase A2) PLA2G4F (1); PLA2G4A (3)  JMJD7-PLA2G4B (1)  
PLC  (Phospholipase – Phospholipase C) PLCB1 (3); PLCB3 (2); PLCB4 (1)    PLCB3 (2)  
PP2B (Protein phophatase - Calcium-dependent, calmodulin-
stimulated protein phosphatase) 
PPP3CA (1); PPP3CB (7)  PPP3CB (1)  
PKA (Protein kinase - cAMP-dependent protein kinase) PRKACB (21)  PRKACB (4); PRKCA (1)  
SHANK (SHANK – scaffold protein) 
SKANK1(1); SHANK2 (4); SHANK3 
(2)  
SKANK1 (3); SHANK3 (3)  
EAAT (Sodium:dicarboxylate (SDF) transporter - Sodium-
dependent glutamate/aspartate transporter ) 
SLC1A1 (2); SLC1A7 (1)    - 
RGS (Regulator of G-protein signaling) RGS7 (1)  RGS4 (1)  
